MUC1 intracellular bioactivation mediates lung fibrosis

Background Serum KL6/mucin 1 (MUC1) has been identified as a potential biomarker in idiopathic pulmonary fibrosis (IPF), but the role of MUC1 intracellular bioactivation in IPF is unknown. Objective To characterise MUC1 intracellular bioactivation in IPF. Methods and results The expression and phosphorylation of Thr(41) and Tyr(46) on the intracellular MUC1-cytoplasmic tail (CT) was increased in patients with IPF (n=22) compared with healthy subjects (n=21) and localised to fibroblasts and hyperplastic alveolar type II cells. Transforming growth factor (TGF)-beta 1 phosphorylated SMAD3 and thereby increased the phosphorylation of MUC1-C T Thr(41) and Tyr(46) in lung fibroblasts and alveolar type II cells, activating beta-catenin to form a phospho-S mad3/MUC1-C T and MUC1-C T/beta-catenin nuclear complex. This nuclear complex promoted alveolar epithelial type II and fibroblast to myofibroblast transitions, as well as cell senescence and fibroblast proliferation. The inhibition of MUC1-C T nuclear translocation using the inhibitor, GO-201 or silencing MUC1 by siRNA, reduced myofibroblast transition, senescence and proliferation in vitro. Bleomycin-induced lung fibrosis was reduced in mice treated with GO-201 and in MUC1-knockout mice. The profibrotic lectin, galectin-3, directly activated MUC1-C T and served as a bridge between the TGF-beta receptor and the MUC1-C domain, indicating TGF-beta 1-ependent and TGF-beta 1-independent intracellular bioactivation of MUC1. Conclusions MUC1 intracellular bioactivation is enhanced in IPF and promotes fibrotic processes that could represent potential druggable targets for IPF.